NA
GMAB icon

NewEdge Advisors’s Genmab GMAB Stock Holding History

NewEdge Advisors’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.91K Hold
71
– – ﹤0.01% 3820
2025
Q4 		$2.19K Sell
71
-1,165
-94% -$36.3K ﹤0.01% 3870
2025
Q3 		$37.9K Buy
1,236
+1,143
+1,229% +$27.9K ﹤0.01% 2917
2025
Q2 		$1.92K Sell
93
-11,443
-99% -$235K ﹤0.01% 3627
2025
Q1 		$226K Sell
11,536
-7,768
-40% -$163K ﹤0.01% 2043
2024
Q4 		$403K Buy
19,304
+2,171
+13% +$47.7K ﹤0.01% 1685
2024
Q3 		$418K Buy
17,133
+1,767
+11% +$47.2K ﹤0.01% 1580
2024
Q2 		$386K Buy
15,366
+14,291
+1,329% +$405K ﹤0.01% 1571
2024
Q1 		$32.2K Sell
1,075
-310
-22% -$9.11K ﹤0.01% 2455
2023
Q4 		$44.1K Buy
1,385
+711
+105% +$22.3K ﹤0.01% 2269
2023
Q3 		$23.8K Buy
674
+80
+13% +$3.05K ﹤0.01% 2338
2023
Q2 		$22.6K Sell
594
-2,406
-80% -$95.9K ﹤0.01% 2350
2023
Q1 		$113K Buy
3,000
+110
+4% +$4.23K ﹤0.01% 1705
2022
Q4 		$5.33K Buy
+2,890
New +$119K ﹤0.01% 2568

Other funds holding GMAB

OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

NewEdge Advisors's GMAB Position: Q1 2026 in Review

NewEdge Advisors held its Genmab (GMAB) position steady in Q1 2026 at 71 shares worth $1.91K. The position accounts for ﹤0.01% of the portfolio, ranked #3820.

NewEdge Advisors first reported a position in GMAB in Q4 2022 and has held it in 14 quarters since. The position peaked at $418K in Q3 2024. 272 funds tracked by Wall St. Rank hold GMAB as of Q1 2026.

  • NewEdge Advisors held 71 shares of Genmab worth $1.91K as of Q1 2026.
  • NewEdge Advisors left its Genmab share count unchanged in Q1 2026.
  • Genmab made up ﹤0.01% of NewEdge Advisors's portfolio in Q1 2026, its #3820 holding.
  • NewEdge Advisors first reported a position in Genmab in Q4 2022 and has held it in 14 quarters since.
  • NewEdge Advisors's Genmab position peaked at $418K in Q3 2024.
  • 272 funds tracked by Wall St. Rank held Genmab as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.